Continuing operations (in dollars per share)
Edwards Lifesciences Continuing operations (in dollars per share) increased by 500.0% to $0.66 in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.5%, from $0.62 to $0.66. Over 3 years (FY 2022 to FY 2025), Continuing operations (in dollars per share) shows a downward trend with a -5.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
Higher values indicate stronger core operational performance and efficiency in generating returns for shareholders.
Detailed definition
This metric measures the diluted earnings per share derived exclusively from the company's ongoing, core business activi...
Peer comparison
Widely used by analysts to evaluate the core health of a business, excluding one-time or non-recurring divestiture impacts.
eps_income_loss_from_continuing_operations_per_diluted_shareHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.53 | $0.53 | $0.53 | $0.53 | $0.49 | $0.41 | $0.55 | $0.55 | $0.54 | $0.61 | $0.61 | $0.58 | $0.62 | $0.57 | $0.50 | $0.11 | $0.66 |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -7.5% | -16.3% | +34.1% | +0.0% | -1.8% | +13.0% | +0.0% | -4.9% | +6.9% | -8.1% | -12.3% | -78.0% | +500.0% |
| YoY Change | — | — | — | — | -7.5% | -22.6% | +3.8% | +3.8% | +10.2% | +48.8% | +10.9% | +5.5% | +14.8% | -6.6% | -18.0% | -81.0% | +6.5% |
Continuing operations (in dollars per share) at Other Companies
Frequently Asked Questions
- What is Edwards Lifesciences's continuing operations (in dollars per share)?
- Edwards Lifesciences (EW) reported continuing operations (in dollars per share) of $0.66 in Q1 2026.
- How has Edwards Lifesciences's continuing operations (in dollars per share) changed year-over-year?
- Edwards Lifesciences's continuing operations (in dollars per share) increased by 6.5% year-over-year, from $0.62 to $0.66.
- What is the long-term trend for Edwards Lifesciences's continuing operations (in dollars per share)?
- Over 3 years (2022 to 2025), Edwards Lifesciences's continuing operations (in dollars per share) has grown at a -5.3% compound annual growth rate (CAGR), from $2.12 to $1.80.
- What does continuing operations (in dollars per share) mean?
- The profit per share generated solely from the company's primary, ongoing business operations, accounting for potential dilution.